{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/urethritis-male/prescribing-information/ofloxacin/","result":{"pageContext":{"chapter":{"id":"ecf258dc-1499-5f7a-a781-6566ea1a4f54","slug":"ofloxacin","fullItemName":"Ofloxacin","depth":2,"htmlHeader":"<!-- begin field 838e8164-6100-41dd-a90e-aac901723be4 --><h2>Ofloxacin</h2><!-- end field 838e8164-6100-41dd-a90e-aac901723be4 -->","summary":"","htmlStringContent":"<!-- begin item 8de17f37-7ec1-482e-9203-aac901723b86 --><!-- end item 8de17f37-7ec1-482e-9203-aac901723b86 -->","topic":{"id":"f36465a1-1338-5604-8bb2-c8e555c598ae","topicId":"9d634e3c-7474-4d96-bbcb-7c29c10c1b03","topicName":"Urethritis - male","slug":"urethritis-male","lastRevised":"Last revised in September 2019","chapters":[{"id":"ac50911c-3aae-5117-95ce-67557d49723a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ae05a825-47bf-5fc0-9065-c859d8427b3b","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1c94ea5f-b73f-51a3-9d99-83814d055e3f","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8e3d5f57-add8-5b6f-bd13-9ea05bc5ec30","slug":"changes","fullItemName":"Changes"},{"id":"7353c5be-d0ed-506f-8487-265ce270e97f","slug":"update","fullItemName":"Update"}]},{"id":"644de86f-bfeb-5ebf-8cda-c1be15f8938a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bd23c29c-af09-54b6-be4e-9f6ed812d62a","slug":"goals","fullItemName":"Goals"},{"id":"63346f4c-c71f-5887-b6d3-0d07661b1393","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"49121260-b8cb-5ecc-855a-f87303bc727e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"40b6a387-e841-594d-8616-fb4e8f4391e1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7d3a51c9-f614-5196-8052-55ceb4b6cf08","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b2b68ef0-16c8-5dbc-b8f8-fbdfa673ed3f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"027c2bf3-1625-560c-902b-9fef54935849","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"95898c97-d200-5648-b696-7388ab850318","slug":"definition","fullItemName":"Definition"},{"id":"9b0e6aa9-b665-52de-bfa3-93f09f83bc3d","slug":"causes","fullItemName":"Causes"},{"id":"f9c36294-6c74-5b9e-8afb-65b38bfa14e1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2d0fc428-15ca-543a-bd93-b4ac231ed0cb","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"b7be062a-0eff-5e83-9493-809927e4776a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"60b1f452-fec4-567e-b8f0-39660841e61b","slug":"when-to-suspect-urethritis","fullItemName":"When to suspect urethritis"},{"id":"d5d984a2-a3d7-533a-9b94-02ac51c4fa07","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"75471ada-cb93-59f3-97b0-3c182e9f80b7","fullItemName":"Management","slug":"management","subChapters":[{"id":"b6607a10-84f2-51a2-ac03-a68ccb8dcbe9","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"513fcd9d-25a9-5183-98b5-32bdef8e6d5a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6598b6d1-3e66-518c-9a8b-63eff17fecaf","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"c498c9de-1083-50a6-b290-ac30aebda851","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"ecf258dc-1499-5f7a-a781-6566ea1a4f54","slug":"ofloxacin","fullItemName":"Ofloxacin"},{"id":"f4c18a1e-b367-5433-ac91-efd9bce81a5e","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"221c9f46-f915-5e6f-8275-959420090646","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"25917416-1fc8-5919-9773-f3b7e054b6a0","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2ad44d6a-7cb1-598d-9dd4-9552f4f7fb49","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"791a5ccc-3882-5e9e-a55e-fc18bff5d67a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7370a44f-6a25-58d8-a772-568023fd6516","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"991288b5-d1b7-50f9-8e87-ceaf3331e0e2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"bf8f6743-57dd-5f6e-9460-bbecad8fd0b5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b2d086b7-cf3d-5d24-994a-e0280f2397db","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"513fcd9d-25a9-5183-98b5-32bdef8e6d5a","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"b2a07364-5a0f-5e83-aa66-c64db9372106","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 8aa45a2e-bbff-44c1-9d31-aac901725d15 --><h3>Contraindications and cautions</h3><!-- end field 8aa45a2e-bbff-44c1-9d31-aac901725d15 -->","summary":"","htmlStringContent":"<!-- begin item d4b16ea6-1aae-4216-ae26-aac901725cd8 --><!-- begin field ff35d754-73b7-4521-acee-aac901725d15 --><ul><li><strong>Do not prescribe ofloxacin to a people with:</strong><ul><li>A history of a serious adverse reaction to fluoroquinolone antibiotics (including tendinitis or tendon rupture, muscle pain, muscle weakness, joint pain, joint swelling, peripheral neuropathy, and CNS effects).</li><li>A history of epilepsy or an existing central nervous system disorder with a lowered seizure threshold.</li><li>Latent or actual defects in glucose-6-phosphate dehydrogenase activity (may be prone to haemolytic reactions when treated with quinolone antibacterial agents).</li></ul></li><li><strong>Prescribe ofloxacin with caution to people:</strong><ul><li>At risk of aortic aneurysm and dissection — the MHRA advises that benefit-risk should be assessed and other therapeutic options considered before using fluoroquinolones in this group of people.</li><li>Over the age of 60 years — due to increased risk of tendon injury.</li><li>Who have received a solid organ transplant — due to increased risk of tendon injury.</li><li>With impaired renal function — dose adjustment may be required.</li><li>With impaired liver function — advise the person to stop treatment and seek medical advise if signs and symptoms of hepatic disease develop such as anorexia, jaundice, dark urine, pruritus or tender abdomen.</li><li>With a history of psychotic disorder or psychiatric disease — psychotic reactions have been reported.</li><li>Who may be predisposed to prolongation of the QT interval. This includes people:<ul><li>With congenital or documented acquired QT prolongation.</li><li>Currently receiving treatment with other active substances known to prolong the QT interval such as antiarrhythmics of classes IA and III.</li><li>With electrolyte disturbance, particularly in cases of hypokalaemia and hypomagnesaemia.</li><li>With clinically relevant bradycardia, cardiac arrhythmia, or severe cardiac insufficiency.</li></ul></li><li>With myasthenia gravis — may exacerbate muscle weakness.</li><li>With diabetes — careful monitoring of blood glucose is recommended due to risk of dysglycaemia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">MHRA, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">MHRA, 2019</a>] </p><p> </p><!-- end field ff35d754-73b7-4521-acee-aac901725d15 --><!-- end item d4b16ea6-1aae-4216-ae26-aac901725cd8 -->","subChapters":[]},{"id":"1122bcd9-bdc3-51bd-81f1-22927a1dda85","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 7362f789-8f92-4ad0-ae0c-aac90172692e --><h3>Adverse effects</h3><!-- end field 7362f789-8f92-4ad0-ae0c-aac90172692e -->","summary":"","htmlStringContent":"<!-- begin item 09620255-9c29-49eb-9e50-aac9017268f2 --><!-- begin field 66f89beb-4810-4d8a-8580-aac90172692e --><p><strong>Adverse effects of ofloxacin include:</strong></p><ul><li>Gastrointestinal effects — for example diarrhoea and nausea.</li><li>Musculoskeletal (very rare) — tendon damage. The risk of tendon rupture is increased by co-administration of corticosteroids.</li><li>Antibiotic-associated colitis (rare). </li><li>Pseudomembranous colitis (very rare) — consider this if a person develops severe diarrhoea during or after treatment with ofloxacin.<ul><li>Pseudomembranous colitis is an acute, exudative colitis caused by Clostridium difficile, a Gram-positive toxin-releasing bacillus. It often follows antibiotic treatment. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li>Central nervous system — Quinolones may lower the seizure threshold and may trigger seizures. In addition drowsiness and impaired performance of skilled tasks (such as driving) can be occasionally caused by ofloxacin. Advise the person to use caution when driving a car or operating machinery.  </li><li>Cardiovascular system — there is an increased risk of aortic aneurysm and dissection after intake of fluoroquinolones, particularly in the older population.</li><li>Other adverse effects include: <ul><li>Uveitis. </li><li>Severe liver injury.</li><li>Exfoliative dermatitis (frequency unknown).</li></ul></li><li><strong>NOTE: advice from the MHRA/CHM states that fluoroquinolones can <em>very rarely</em> cause long-lasting (up to months or years), disabling, and potentially irreversible side effects, sometimes affecting multiple systems, organ classes, and senses.</strong> People should be advised to stop treatment at the first signs of a serious adverse reaction, such as tendonitis or tendon rupture, muscle pain, muscle weakness, joint pain, joint swelling, peripheral neuropathy, and central nervous system effects, and to contact their doctor immediately for further advice.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">MHRA, 2019</a>] </p><!-- end field 66f89beb-4810-4d8a-8580-aac90172692e --><!-- end item 09620255-9c29-49eb-9e50-aac9017268f2 -->","subChapters":[]},{"id":"b33ce8c7-d869-5127-9b8a-425b40250458","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field e905ea2d-3889-4e63-91bd-aac901727448 --><h3>Drug interactions</h3><!-- end field e905ea2d-3889-4e63-91bd-aac901727448 -->","summary":"","htmlStringContent":"<!-- begin item a2549ce8-7475-4c11-8011-aac90172740c --><!-- begin field 7b71dc37-36b9-413f-adf7-aac901727448 --><p><strong>Key drug interactions with ofloxacin include: </strong></p><ul><li><strong>Corticosteroids</strong> — co-administration increases the risk of tendon damage.</li><li><strong>Drugs that prolong the QT interval </strong>(such as Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, and antipsychotics) — very rare cases of QT interval prolongation have been reported in people taking quinolones and they should therefore be prescribed with caution alongside drugs known to prolong the QT interval.</li><li><strong>Antacids</strong> — should preferably not be taken at the same time as quinolones as they may impair its absorption.</li><li><strong>Coumarins</strong> — quinolones may enhance the anticoagulant effect, increasing the risk of bleeding. Check the INR within 3–5 days of starting the quinolone.<ul><li>Advise people taking warfarin to seek immediate medical advice if they experience spontaneous bleeding, and the bleeding does not stop or recurs. This includes bruising, bleeding gums, nosebleeds, prolonged bleeding from cuts, and blood in the urine or stools.</li></ul></li><li><strong>Theophylline</strong> — quinolones given concurrently with theophylline, may reduce the seizure threshold. Monitor theophylline concentration closely.</li><li><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs)</strong> — possible increased risk of seizures when quinolones are given with NSAIDs. Avoid concurrent use in people with epilepsy or people predisposed to seizures, or monitor them very closely.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 7b71dc37-36b9-413f-adf7-aac901727448 --><!-- end item a2549ce8-7475-4c11-8011-aac90172740c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}